Analysis of Accumulated SARS-CoV-2 Seroconversion in North Carolina: The COVID-19 Community Research Partnership

Jc, Williamson; Tf, Wierzba; Santacatterina, Michele; Munawar, Iqra; Al, Seals; Ca, Pittman Ballard; Alexander-Miller, Martha A.; Ms, Runyon; Lh, McCurdy; Ma, Gibbs; Ahmed, Amina; Wh, Lagarde; Pd, Maguire; King-Thiele, Robin; Hamrick, Terri S.; Ihmeidan, Abdalla; Henderson, Shakira; Uschner, Diane; Dm, Herrington; Jw, Sanders

doi:10.1101/2021.03.11.21253226

Cited by 3 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the emergence of the virus, young populations have also been found to have high seroprevalence and should not be overlooked [40,96]. The impact of social disadvantage was documented in the general population and blood donors in a comparison of seroprevalence according to income [32,47,68,104,126,[129][130][131][132][133][134] or education level [18,19,20,47,48,53,57,68,82,99,[130][131][132][133][134][135][136][137][138]. Prevalence was higher in the lowest than highest income groups (prevalence doubled [32], from 1.8% to 3.7%).…”

Section: Plos Onementioning

confidence: 99%

Seroprevalence and SARS-CoV-2 invasion in general populations: A scoping review over the first year of the pandemic

et al. 2023

View full text Add to dashboard Cite

Since the beginning of the COVID-19 pandemic, counting infected people has underestimated asymptomatic cases. This literature scoping review assessed the seroprevalence progression in general populations worldwide over the first year of the pandemic. Seroprevalence studies were searched in PubMed, Web of Science and medRxiv databases up to early April 2021. Inclusion criteria were a general population of all ages or blood donors as a proxy. All articles were screened for the title and abstract by two readers, and data were extracted from selected articles. Discrepancies were resolved with a third reader. From 139 articles (including 6 reviews), the seroprevalence estimated in 41 countries ranged from 0 to 69%, with a heterogenous increase over time and continents, unevenly distributed among countries (differences up to 69%) and sometimes among regions within a country (up to 10%). The seroprevalence of asymptomatic cases ranged from 0% to 31.5%. Seropositivity risk factors included low income, low education, low smoking frequency, deprived area residency, high number of children, densely populated centres, and presence of a case in a household. This review of seroprevalence studies over the first year of the pandemic documented the progression of this virus across the world in time and space and the risk factors that influenced its spread.

show abstract

Section: Plos Onementioning

confidence: 99%

Seroprevalence and SARS-CoV-2 invasion in general populations: A scoping review over the first year of the pandemic

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The second publication from the COVID-19 Community Research Partnership focused on analyzing 49,000 serological results from 17,000 participants in the North Carolina region [ 16 ]. The purpose of the study was to provide an estimation of infection rates or presence of antibodies to SARS-CoV-2 over the duration of the study (Apr 2020–Feb 2021).…”

Section: Analysis Of Antibodies From Dried Mitra Samplesmentioning

confidence: 99%

Volumetric Absorptive Microsampling: Its Use in Covid-19 Research and Testing

Rudge¹,

Kushon²

2021

Bioanalysis

View full text Add to dashboard Cite

COVID-19 led to changes in the way blood samples are collected. As societies were isolated to control viral spread, access to facilities became limited. Remote sample collection with a volumetric microsampling approach, using Mitra® devices based on VAMS® technology, proved to be highly effective. It allowed people to collect high-quality samples at home and post them to a laboratory. This enabled scientists to conduct large serosurveillance studies, with results showing that seroprevalence of COVID-19 was higher than initially expected. Furthermore, remote microsampling studies by several institutions were conducted to measure the relationship between antigen levels and antibody response and duration. VAMS technology was also used in COVID-19 clinical trials. In summary, the independent research reviewed in this paper proved that VAMS is an effective sample collection alternative.

show abstract

“…43,44 Other samples consider special populations, including healthcare and industrial livestock workers. 45,46 We present the first seroprevalence estimates from a probability-based cohort in North Carolina.…”

mentioning

confidence: 99%

Estimation of SARS-CoV-2 Seroprevalence in Central North Carolina: Accounting for Outcome Misclassification in Complex Sample Designs

Vias,

Cassidy,

Edwards

et al. 2023

Epidemiology

View full text Add to dashboard Cite

Background: Population-based seroprevalence studies are crucial to understand community transmission of COVID-19 and guide responses to the pandemic. Seroprevalence is typically measured from diagnostic tests with imperfect sensitivity and specificity. Failing to account for measurement error can lead to biased estimates of seroprevalence. Methods to adjust seroprevalence estimates for the sensitivity and specificity of the diagnostic test have largely focused on estimation in the context of convenience sampling. Many existing methods are inappropriate when data are collected using a complex sample design. Methods: We present methods for seroprevalence point estimation and confidence interval construction that account for imperfect test performance for use with complex sample data. We apply these methods to data from the Chatham County COVID-19 Cohort (C4), a longitudinal seroprevalence study conducted in central North Carolina. Using simulations, we evaluate bias and confidence interval coverage for the proposed estimator compared with a standard estimator under a stratified, three-stage cluster sample design. Results: We obtained estimates of seroprevalence and corresponding confidence intervals for the C4 study. SARS-CoV-2 seroprevalence increased rapidly from 10.4% in January to 95.6% in July 2021 in Chatham County, North Carolina. In simulation, the proposed estimator demonstrates desirable confidence interval coverage and minimal bias under a wide range of scenarios. Conclusion: We propose a straightforward method for producing valid estimates and confidence intervals when data are based on a complex sample design. The method can be applied to estimate the prevalence of other infections when estimates of test sensitivity and specificity are available.

show abstract

Analysis of Accumulated SARS-CoV-2 Seroconversion in North Carolina: The COVID-19 Community Research Partnership

Cited by 3 publications

References 26 publications

Seroprevalence and SARS-CoV-2 invasion in general populations: A scoping review over the first year of the pandemic

Seroprevalence and SARS-CoV-2 invasion in general populations: A scoping review over the first year of the pandemic

Volumetric Absorptive Microsampling: Its Use in Covid-19 Research and Testing

Estimation of SARS-CoV-2 Seroprevalence in Central North Carolina: Accounting for Outcome Misclassification in Complex Sample Designs

Contact Info

Product

Resources

About